parkinson's disease triple agonist glp-1 gip glucagon clinical trial Glucagon-like peptide-1 receptor: mechanisms and advances in therapy Are GLP-1 diabetes drugs like

Here, we provide a comprehensive review of the therapeutic potential of incretin mimetics and insulin in AD and PD.

This breakthrough formula fires up GLP-1 production to fend off cravings, especially those carb-loaded temptations

The dual GIP/GLP-1 receptor agonist tirzepatide is among the furthest developed multi-agonists for diabetes care and has so far displayed promising nephroprotective effects

All Day

Ozempic changed the conversation around weight loss in a way that almost nothing has in the past twenty years

Purpose Chronic kidney disease (CKD) is one of the most common complications of type 2 diabetes (T2D), and CKD-related disability and mortality are increasing despite the recent advances in diabetes management